1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Cuorips Inc.

Cuorips Inc.

TTSE:4894
6,370.00
JPY
-630.00
(-9.00%)
57.88BMarket Cap
Nov 13Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.03
1.84
5.08
3.14
21.89
25.86
- -
Basic EPS, GAAP
-40.81
-49.76
-59.94
-85.87
-80.52
-124.55
- -
Free Cash Flow per Basic Share
-126.09
-33.07
-54.65
-66.15
-112.78
-135.15
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
560.32
516.95
458.31
752.26
682.9
575.28
- -
Tangible Book Value per Share
560.32
516.95
457.58
750.12
679.16
559.78
- -
Basic Weighted Avg Shares
8
8
8
7
8
8
8
Sales/Revenue/Turnover
- -
14
38
23
175
212
- -
Operating Margin (%)
-128,109.55
-2,682.85
-1,176.75
-2,547.34
-336.9
-509.23
- -
Depreciation Expense
74
93
79
70
77
84
- -
Net Income, GAAP
-308
-375
-452
-632
-644
-1,023
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-139,924.55
-2,697.74
-1,181.04
-2,736.49
-367.76
-481.62
- -
Working Capital
3,514
3,255
2,880
5,446
4,948
4,143
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
4,222
3,896
3,454
5,984
5,530
4,769
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-9.25
-12.3
-13.4
-11.2
-19.9
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
57,457
57,885
35,719

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
4,866
4,421
- -
Cash, Cash Equivalents & STI
4,071
3,900
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
26
65
- -
Total Current Liabilities
115
278
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6.57%
-13.75%
Free Cash Flow
- -
23.58%
22.96%
Net Income, GAAP
- -
28.57%
58.71%
Sales/Revenue/Turnover
- -
1,407.83%
21.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
175
2026
- -
- -
- -
- -
212
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-80.52
2026
- -
- -
- -
- -
-124.55
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Takayuki Kusanagi
Full Time Employees
51
Sector
Health technology
Industry
Biotechnology
Address
Nakanoshima Qross 8F, O-Nexus Tokyo Japan 530-0005
IPO Date
Jun 27, 2023
Website
cuorips.co.jp
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Cuorips Inc. (4894.T) develops, manufactures, commercializes, and sells human induced pluripotent stem (iPS) cell-derived cardiomyocyte sheets and related regenerative medical products. The company offers core products including human (allogeneic) iPS cell-derived cardiomyocyte patches for treating severe heart failure, such as ischemic cardiomyopathy, through angiogenesis induction and cardiac performance support; cellular and tissue-based products; cell processing products; and contract development and manufacturing organization (CDMO) services utilizing its CLiC-1 commercial cell culture and processing facility in Minoh, Osaka. It also provides consulting services for cellular and tissue-based products and operates in the regenerative medicine sector, targeting patients with cardiovascular diseases and pharmaceutical partners via in-house research, university collaborations, and joint ventures. Founded in 2017 as a spin-off from Osaka University and headquartered in Tokyo, Japan, with facilities in Tokyo, Suita, and Minoh, Osaka, Cuorips maintains a global network including subsidiaries Cuorips Healthcare Science in Japan and iReheart Inc. in North America. Recent developments include a joint research agreement with Stanford University’s Department of Cardiothoracic Surgery announced in December 2024 to advance cardiovascular therapies; an application for manufacturing and marketing approval of human (allogeneic) iPS cell-derived cardiomyocyte patches submitted in April 2025; participation in Japan Health in June 2025; and a 2023 listing on the Tokyo Stock Exchange Growth Market, alongside prior expansions like the 2020 commercial launch of CLiC-1.